The recent discovery of recurrent IDH mutations in cancer led to the rapid development of small molecule targeted inhibitors, which effectively inhibit the 2HG oncometabolite and promote the restoration of normal myeloid differentiation18. The gene discussed is IDH1; the disease is cancer.